Molecular Virology of Hepatitis B Virus for Clinicians

Clinics in Liver Disease

Volumn 11, Issue 4, 2007, Pages 685-706

  Block, Timothy M ^a,b   Guo, Haitao ^a   Guo, Ju Tao ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HEPATITIS B FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON A; ANTIVIRUS AGENT; CAPSID PROTEIN; CIRCULAR DNA; DOUBLE STRANDED DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; POLYPEPTIDE; PROTEIN X; TELBIVUDINE; VIRUS PROTEIN; VIRUS RNA;

CHRONIC ACTIVE HEPATITIS; CLINICAL FEATURE; DNA SYNTHESIS; DRUG INHIBITION; GENE MUTATION; GENE STRUCTURE; GENE TRANSLOCATION; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE PERSONNEL; HEPADNAVIRIDAE; HEPATITIS B; HEPATITIS B VIRUS; HISTORY OF MEDICINE; HOST RANGE; HUMAN; IMMUNIZATION; INTERVENTION STUDY; LIFE CYCLE; LIVER CELL CARCINOMA; LIVER CELL CULTURE; LIVER CIRRHOSIS; MOLECULAR BIOLOGY; MORPHOGENESIS; NONHUMAN; REVIEW; VIRUS CARRIER; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 35548983363     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.08.002     Document Type: Review

References (98)

1. Seeger C., and Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 64 (2000) 51-68
2. Ganem D., and Prince A.M. Hepatitis B infection: natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
3. Menne S., and Tennant B.C. Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Nat Med 5 (1999) 1125-1126
4. Guo H., Mason W.S., Aldrich C.E., et al. Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity. J Virol 79 (2005) 2729-2742
5. Hoofnagle J.H., and di Bisceglie A.M. The treatment of chronic viral hepatitis. N Engl J Med 336 (1997) 347-356
6. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin Liver Dis 25 (2005) 3-8
7. Wang G.H., and Seeger C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71 (1992) 663-670
8. Wang G.H., and Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. J Virol 67 (1993) 6507-6512
9. Hu J., Toft D.O., and Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J 16 (1997) 59-68
10. Milich D.R. Pathobiology of acute and chronic hepatitis B virus infection: an introduction. J Viral Hepat 4 (1997) 25-30
11. Milich D.R., and Liang T.J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38 (2003) 1075-1086
12. Guidotti L.G., Rochford R., Chung J., et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284 (1999) 825-829
13. Walter E., Keist R., Niederost B., et al. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. Hepatology 24 (1996) 1-5
14. Jilbert A.R., Miller D.S., Scougall C.A., et al. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. Virology 226 (1996) 338-345
15. Jilbert A.R., Botten J.A., Miller D.S., et al. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection. Virology 244 (1998) 273-282
16. Paran N., Geiger B., and Shaul Y. HBV infection of cell culture: evidence for multivalent and cooperative attachment. EMBO J 20 (2001) 4443-4453
17. Acs G., Sells M.A., Purcell R.H., et al. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc.Natl.Acad.Sci.USA 84 (1987) 4641-4644
18. Sureau C., Eichberg J.W., Hubbard G.B., et al. A molecularly cloned hepatitis B virus produced in vitro is infectious in a chimpanzee. J.Virol 62 (1988) 3064-3067
19. Sureau C., Romet-Lemonne J., Mullins J.I., et al. Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell 47 (1987) 37-47
20. Gripon P., Rumin S., Urban S., et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99 (2002) 15655-15660
21. Tai P.C., Suk F.M., Gerlich W.H., et al. Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology 292 (2002) 44-58
22. Urban S., and Gripon P. Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein. J Virol 76 (2002) 1986-1990
23. Gripon P., Cannie I., and Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79 (2005) 1613-1622
24. Schmitt S., Glebe D., Alving K., et al. Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J Biol Chem 274 (1999) 11945-11957
25. Lu X., Block T.M., and Gerlich W.H. Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line. J Virol 70 (1996) 2277-2285
26. Kann M., Schmitz A., and Rabe B. Intracellular transport of hepatitis B virus. World J Gastroenterol 13 (2007) 39-47
27. Andreyav H.J.N., Norman A.R., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85 (2001) 692-696
28. Kann M., Sodeik B., Vlachou A., et al. Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex. J Cell Biol 145 (1999) 45-55
29. Yeh C.T., Chiu H.T., Chu C.M., et al. G1 phase dependent nuclear localization of relaxed-circular hepatitis B virus DNA and aphidicolin-induced accumulation of covalently closed circular DNA. J Med Virol 55 (1998) 42-50
30. Summers J., O'Connell A., and Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci USA 72 (1975) 4597-4601
31. Lien J.M., Aldrich C.E., and Mason W.S. Evidence that a capped oligoribonucleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis. J Virol 57 (1986) 229-236
32. Newbold J.E., Xin H., Tencza M., et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 69 (1995) 3350-3357
33. Block T.M., Mehta A.S., Fimmel C.J., et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22 (2003) 5093-5107
34. Summers J., Jilbert A.R., Yang W., et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 100 (2003) 11652-11659
35. Zhang Y.Y., Zhang B.H., Theele D., et al. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci USA 100 (2003) 12372-12377
36. Tong Q.S., Zheng L.D., Wang L., et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 12 (2005) 509-514
37. Tong S.P., Li J.S., Vitvitski L., et al. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology 176 (1990) 596-603
38. Ou J.H. Molecular biology of hepatitis B virus e antigen. J Gastroenterol Hepatol 12 (1997) S178-S187
39. Liaw Y.F. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 12 Suppl 1 (2001) 67-71
40. Seeger C., and Mason W.S. Replication of the hepatitis virus genome. In: DePamphilis M.L. (Ed). DNA replication in eukaryotic cells (1996), Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY) 815-831
41. Moolla N., Kew M., and Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat 9 (2002) 323-331
42. Henkler F.F., and Koshy R. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Viral Hepat 3 (1996) 109-121
43. Obert S., Zachmann-Brand B., Deindl E., et al. A spliced hepadnavirus RNA is essential for virus replication. EMBO J 15 (1996) 2565-2574
44. Wei Y., Tavis J.E., and Ganem D. Relationship between viral DNA synthesis and virion envelopment in hepatitis B virus. J Virol 70 (1997) 6455-6458
45. Perlman D., and Hu J. Duck hepatitis B virus virion secretion requires a double-stranded DNA genome. J Virol 77 (2003) 2287-2294
46. Perlman D.H., Berg E.A., O'Connor P.B., et al. Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsids. Proc Natl Acad Sci USA 102 (2005) 9020-9025
47. Wu T.T., Coates L., Aldrich C.E., et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175 (1990) 255-261
48. Lenhoff R.J., and Summers J. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol 68 (1994) 4565-4571
49. Summers J., Smith P.M., and Horwich A.L. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 64 (1990) 2819-2824
50. Block T.M., Mehta A.S., Blumberg B.S., et al. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasome degradation and enhance chronicity?. DNA Cell Biol 25 (2006) 165-170
51. Ostapchuk P., Hearing P., and Ganem D. A dramatic shift in the transmembrane topology of a viral envelope glycoprotein accompanies hepatitis B viral morphogenesis. EMBO J 13 (1994) 1048-1057
52. Bruss V., and Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA 88 (1991) 1059-1063
53. Guo J.T., and Pugh J.C. Topology of the large envelope protein of duck hepatitis B virus suggests a mechanism for membrane translocation during particle morphogenesis. J Virol 71 (1997) 1107-1114
54. Prange R., and Streeck R.E. Novel transmembrane topology of the hepatitis B virus envelope proteins. EMBO J 14 (1995) 247-256
55. Persing D.H., Varmus H.E., and Ganem D. The preS1 protein of hepatitis B virus is acylated at its amino terminus with myristic acid. J Virol 61 (1987) 1672-1677
56. Yu M., and Summers J. A domain of the hepadnavirus capsid protein is specifically required for DNA maturation and virus assembly. J Virol 65 (1991) 2511-2517
57. Pugh J., Zweidler A., and Summers J. Characterization of the major duck hepatitis B virus core particle protein. J Virol 63 (1988) 1371-1376
58. Chisari F.V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 156 (2000) 1117-1132
59. Rehermann B., Lau D., Hoofnagle J.H., et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97 (1996) 1655-1665
60. Guidotti L.G., Morris A.G., Mendez H., et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J Virol 76 (2002) 2617-2621
61. Webster J.M.G., Reignat S., Maini M.K., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32 (2000) 1117-1124
62. Webster G., and Bertoletti A. Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 38 (2001) 467-473
63. Su A.I., Pezacki J.P., Wodicka L., et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 99 (2002) 15669-15674
64. Wieland S.F., Guidotti L.G., and Chisari F.V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 74 (2000) 4165-4173
65. Geissler M., Bruss V., Michalak S., et al. Intracellular retention of hepatitis B virus surface proteins reduces interleukin-2 augmentation after genetic immunizations. J Virol 73 (1999) 4284-4292
66. Liu Y., Simsek E., Norton P., et al. The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: development of a novel therapeutic vaccine candidate. Virology 365 (2007) 10-19
67. Gozuacik D., Murakami Y., Saigo K., et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene 20 (2001) 6233-6240
68. Zoulim F., Saputelli J., and Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68 (1994) 2026-2030
69. Dragani T.A., Manenti G., Farza H., et al. Transgenic mice containing hepatitis B virus sequences are more susceptible to carcinogen-induced hepatocarcinogenesis. Carcinogenesis 11 (1990) 953-956
70. Zhou Y.Z., Slagle B.L., Donehower L.A., et al. Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. J Virol 62 (1998) 4224-4231
71. Feitelson M.A. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 181 (1999) 188-202
72. Benn J., and Schneider R.J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 91 (1994) 10350-10354
73. Wang X.W., Forrester K., Yeh H., et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91 (1994) 2230-2234
74. Lee Y.I., Kang-Park S., Do S.I., et al. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 276 (2001) 16969-16977
75. Chisari F., Klopchin K., Morijama T., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59 (1989) 1145-1156
76. Hildt E., Urban S., and Hofschneider P.H. Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator. Oncogene 11 (1995) 2055-2066
77. Hildt E., Urban S., Lauer U., et al. ER-localization and functional expression of the HBV transactivator MHBst. Oncogene 8 (1993) 3359-3367
78. Hildt E., Munz B., Saher G., et al. The preS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. Embo J 21 (2002) 525-535
79. Ciupe S.M., Ribeiro R.M., Nelson P.W., et al. The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci USA 104 (2007) 5050-5055
80. Zhang P., Yu M.Y., Venable R., et al. Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc Natl Acad Sci USA 103 (2006) 9214-9219
81. Xu Z.Y., Liu C.B., Francis D.P., et al. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 76 (1985) 713-718
82. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Morb Mortal Wkly Rep 51 (2002) 1-36
83. Centers for Disease Control and Prevention. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 46 (1997) 1-42
84. Paulij W.P., de Wit P.L., Sunnen C.M., et al. Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. J Gen Virol 80 (1999) 2121-2126
85. Zuckerman J.N., and Zuckerman A.J. Current topics in hepatitis B. J Infect 41 (2000) 130-136
86. Schochetman G., and Kuhns M.C. HIV variants and hepatitis B surface antigen mutants: diagnostic challenges for immunoassays. J Med Virol 78 (2006) S3-S6
87. Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 78 (2006) S43-S47
88. Wieland S.F., Eustaquio A., Whitten-Bauer C., et al. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci USA 102 (2005) 9913-9917
89. Davis M.G., and Jansen R.W. Inhibition of hepatitis B virus in tissue culture by alpha interferon. Antimicrobial Agents & Chemotherapy 38 (1994) 2921-2924
90. Janssen H.L., van Zonneveld M., Senturk H., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
91. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
92. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004) 1750-1758
93. Lai C.L., Rosmawati M., Lao J., et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123 (2002) 1831-1838
94. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 (2000) 172-180
95. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25 (2002) 97-106
96. King R.W., Ladner S.K., Miller T.J., et al. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L- 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 42 (1998) 3179-3186 [published erratum appears in Antimicrob Agents Chemother 1999;43(3):726]
97. Deres K., Schroder C.H., Paessens A., et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299 (2003) 893-896
98. Weber O., Schlemmer K.H., Hartmann E., et al. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 54 (2002) 69-78